Trial Profile
To understand Mechanisms of Resistance to Osimertinib by Circulating Tumor Dna Genotyping in Advanced Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer